Bradley Pharmaceuticals Launches Authorized Generic of ADOXA(R)

    FAIRFIELD, N.J., June 12 /PRNewswire-FirstCall/ -- Bradley
 Pharmaceuticals, Inc. ( BDY) today announced the launch of its
 authorized generic version for ADOXA(R) 150 mg strength doxycycline
 monohydrate tablets. In accordance with a licensing and distribution
 agreement with Par Pharmaceutical Companies, Inc., Par began immediate
 shipments of the 150 mg strength tablets after the approval of another
 generic product. ADOXA(R) is an antibiotic therapy primarily used for the
 treatment of acne.
     "While this strength of ADOXA(R) represented approximately 18.5% of
 Bradley's 2006 net sales, we proactively planned for this launch to
 commence once a generic version became available," stated Daniel Glassman,
 President and CEO of Bradley Pharmaceuticals. "Since 2005, Par has been our
 exclusive partner with authorized generic ADOXA(R) formulations and
 maintains about a 55% market share of previous formulations of ADOXA(R)
 generics, including the 50 mg and 100 mg strengths of ADOXA(R)."
     Important Product Safety Information About ADOXA(R):
     ADOXA(R) Tablets are contraindicated in persons who have shown any
 sensitivity to any of the tetracyclines. The use of drugs of the
 tetracycline class during tooth development (last half of pregnancy,
 infancy, and childhood to 8 years) may cause permanent discoloration of the
 teeth (yellow-gray- brown). Photosensitivity manifested by exaggerated
 sunburn has been observed in some individuals taking tetracyclines.
 Treatment should be discontinued at first evidence of skin erythema.
 Concurrent use of tetracycline may render oral contraceptives less
 effective.
     For additional important information about ADOXA(R), please view full
 prescribing information at www.bradpharm.com or request full prescribing
 information by contacting Bradley Pharmaceuticals.
     Please visit Bradley Pharmaceuticals web site at: www.bradpharm.com.
     About Bradley Pharmaceuticals, Inc.
     Bradley Pharmaceuticals, Inc. was founded in 1985 as a specialty
 pharmaceutical company and markets to niche physician specialties in the
 U.S. and international markets. Bradley's success is based upon its core
 strengths in marketing and sales, which enable the company to Commercialize
 brands that fill unmet patient and physician needs; Develop new products
 through life cycle management; and In-License phase II and phase III drugs
 with long-term intellectual property protection that upon approval leverage
 Bradley's marketing and sales expertise to increase shareholder value.
 Bradley Pharmaceuticals is comprised of Doak Dermatologics, specializing in
 therapies for dermatology and podiatry; Kenwood Therapeutics, providing
 gastroenterology, OB/GYN, respiratory and other internal medicine brands;
 and A. Aarons, which markets authorized generic versions of Doak and
 Kenwood therapies.
     Safe Harbor for Forward-Looking Statements:
     This release contains "forward-looking statements" within the meaning
 of the Private Securities Litigation Reform Act of 1995. Forward-looking
 statements include statements that address activities, events or
 developments that Bradley expects, believes or anticipates will or may
 occur in the future, such as Bradley's plans to in-license, develop and
 launch new and enhanced products with long-term intellectual property
 protection or other significant barriers to market entry, sales and
 earnings estimates, other predictions of financial performance, timing of
 payments on indebtedness, launches by Bradley of new products, market
 acceptance of Bradley's products, and the achievement of initiatives to
 enhance corporate governance and long-term shareholder value.
 Forward-looking statements are based on Bradley's experience and perception
 of current conditions, trends, expected future developments and other
 factors it believes are appropriate under the circumstances and are subject
 to numerous risks and uncertainties, many of which are beyond Bradley's
 control. These risks and uncertainties include Bradley's ability to: launch
 VEREGEN(TM) at the end of 2007 and ELESTRIN(TM) at the end of the second
 quarter 2007; predict the safety and efficacy of these products in a
 commercial setting; estimate sales; maintain adequate inventory levels;
 implement the returns and inventory optimization plan timely, if at all;
 reduce product returns; comply with the restrictive covenants under its
 credit facility; refinance its credit facility; access the capital markets
 on attractive terms or at all; favorably resolve the pending SEC informal
 inquiry; maintain or increase sales of its products; or effectively react
 to other risks and uncertainties described from time to time in Bradley's
 SEC filings, such as fluctuation of quarterly financial results, estimation
 of product returns, chargebacks, rebates and allowances, concentration of
 customers, reliance on third party manufacturers and suppliers, litigation
 or other proceedings (including the pending class action and shareholder
 derivative lawsuits), government regulation and stock price volatility.
 Further, Bradley cannot accurately predict the impact on its business of
 the approval, introduction, or expansion by competitors of generic or
 therapeutically equivalent or comparable versions of Bradley's products or
 of any other competing products. In addition, actual results may differ
 materially from those projected. Bradley undertakes no obligation to
 publicly update any forward-looking statement, whether as a result of new
 information, future events or otherwise.
 
 

SOURCE Bradley Pharmaceuticals, Inc.